Frailty is highly prevalent in chronic kidney disease patients and associated with mortality. We investigated the relationship between frailty and peripheral neuropathy in hemodialysis patients. We enrolled 70 maintenance hemodialysis patients and assessed physical frailty using the five-criteria Fried frailty index. Motor and sensory nerve conduction studies were performed on median, ulnar, peroneal, tibial, and sural nerves. Neuropathy severity was measured using the Total Neuropathy Score (TNS). ANCOVA was performed to control for age and cardiovascular disease as confounders. Patients were categorized as non-frail (n = 25), pre-frail (n = 26), and frail (n = 19). Frail patients were significantly older and had higher cardiovascular disease prevalence. TNS increased progressively across groups (median values: 3 vs 10.5 vs 13, p < .001). After controlling for age and cardiovascular disease, frailty status remained significantly associated with TNS (F(2,65)=6.415, p = .003, partial η2 = 0.165). Electrophysiological studies showed significantly reduced nerve conduction parameters in frail patients. Frailty score strongly correlated with TNS (rs = .48, p < .001). Subgroup analysis in non-diabetic patients confirmed this relationship independent of diabetes status (p = .024). Frailty and peripheral neuropathy demonstrate a strong, independent association in hemodialysis patients that persists after controlling for major confounders. This relationship exists regardless of diabetes status, suggesting peripheral nerve dysfunction is an integral component of frailty in this population. Early recognition could enable targeted interventions to improve outcomes in vulnerable hemodialysis patients.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is responsible for 8–10% of patients with end-stage renal failure. The major extrarenal complications of ADPKD are cardiovascular abnormalities. Interrupted aortic arch (IAA) is a lethal congenital cardiac abnormality seen with a frequency of 3/1000000 births and is defined as a segment of the arcus aorta being atresic. In the literature, there are no any reports showing that polycystic kidney disease and interrupted aortic arch occur together. In this study, we present a rare case in which the patient has polycystic kidney disease and IAA together and discuss whether IAA is a complication of ADPKD.
Background/Objectives: This study investigated the prevalence and clinical significance of glomerular capillary C4d staining in native kidney biopsies and its association with renal outcomes in patients with biopsy-proven glomerular diseases. Methods: This single-center, retrospective study reviewed adult native kidney biopsy cases performed between November 2022 and November 2024 and included 173 patients with biopsy-proven glomerular disease who underwent immunohistochemical C4d staining. Results: C4d positivity was detected in 38.2% of biopsies, most frequently in membranous nephropathy (74.2%), followed by AA amyloidosis (63.6%) and lupus nephritis (63.6%). General characteristics were similar between C4d-negative and C4d-positive patients; however, the C4d-positive group had higher baseline LDL and proteinuria levels and lower albumin levels. At 6 months, the proportion of patients who achieved proteinuria levels <1 g/day and <0.5 g/day was significantly lower in the C4d-positive group compared to the C4d-negative group. The two groups did not differ regarding glomerular filtration rate and the need for renal replacement therapy. Older age and C4d positivity were independently associated with a lower likelihood of achieving proteinuria <0.5 g/day at 6 months. Conclusions: Glomerular capillary C4d positivity was associated with a more pronounced proteinuric phenotype and a reduced likelihood of early proteinuria remission. These findings support the clinical relevance of glomerular capillary C4d staining in relation to early proteinuria remission; however, larger prospective studies incorporating standardized semiquantitative C4d assessment and long-term follow-up are required before C4d can be considered a validated prognostic biomarker.
5 November 2026 in SN Comprehensive Clinical Medicine